AAP
Arax Advisory Partners Portfolio holdings
AUM
$2.18B
1-Year Return
13.41%
This Quarter Return
-0.35%
1 Year Return
+13.41%
3 Year Return
+43.76%
5 Year Return
–
10 Year Return
–
AUM
$1.59B
AUM Growth
+$469M
(+42%)
Cap. Flow
+$481M
Cap. Flow
% of AUM
30.29%
Top 10 Holdings %
Top 10 Hldgs %
26.26%
Holding
2,829
New
215
Increased
1,024
Reduced
629
Closed
414
Top Buys
Top Sells
| 1 |
Vanguard Mid-Cap Value ETF
VOE
|
+$2.95M |
| 2 |
iShares S&P 500 Growth ETF
IVW
|
+$1.47M |
| 3 |
iShares Core High Dividend ETF
HDV
|
+$1.16M |
| 4 |
Schwab US Large-Cap Growth ETF
SCHG
|
+$1M |
| 5 |
Vanguard Intermediate-Term Bond ETF
BIV
|
+$995K |
Sector Composition
| 1 | Technology | 5.92% |
| 2 | Financials | 3.04% |
| 3 | Consumer Discretionary | 2.72% |
| 4 | Healthcare | 2.35% |
| 5 | Industrials | 2.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2201
Home Bancorp
HBCP
$441M
| $878 | ﹤0.01% |
19
-36
| -65% | -$1.66K |
|
|
NB
2202
NioCorp Developments
NB
$345M
| $876 | ﹤0.01% |
565
-60
| -10% | -$93 |
|
2203
FNB Corp
FNB
$5.9B
| $873 | ﹤0.01% |
59
-22
| -27% | -$326 |
|
2204
Yelp
YELP
$2B
| $852 | ﹤0.01% |
22
| – | – |
|
|
MTTR
2205
DELISTED
Matterport, Inc. Class A Common Stock
MTTR
| $849 | ﹤0.01% |
179
+149
| +497% | +$707 |
|
2206
Primoris Services
PRIM
$6.63B
| $841 | ﹤0.01% |
11
-21
| -66% | -$1.61K |
|
2207
TechnipFMC
FTI
$16.6B
| $840 | ﹤0.01% |
29
-50
| -63% | -$1.45K |
|
2208
Aura Biosciences
AURA
$412M
| $839 | ﹤0.01% |
102
+53
| +108% | +$436 |
|
2209
Sabra Healthcare REIT
SBRA
$4.59B
| $832 | ﹤0.01% |
48
| – | – |
|
2210
Hippo Holdings
HIPO
$927M
| $830 | ﹤0.01% |
31
-52
| -63% | -$1.39K |
|
2211
Castle Biosciences
CSTL
$660M
| $827 | ﹤0.01% |
31
| – | – |
|
2212
Weyco Group
WEYS
$293M
| $827 | ﹤0.01% |
22
-65
| -75% | -$2.44K |
|
2213
Acadia Pharmaceuticals
ACAD
$4.08B
| $826 | ﹤0.01% |
45
+1
| +2% | +$18 |
|
2214
FIGS
FIGS
$1.19B
| $824 | ﹤0.01% |
133
-67
| -34% | -$415 |
|
2215
Tompkins Financial
TMP
$1.02B
| $814 | ﹤0.01% |
+12
| New | +$814 |
|
2216
Protagonist Therapeutics
PTGX
$3.71B
| $811 | ﹤0.01% |
+21
| New | +$811 |
|
2217
Hovnanian Enterprises
HOV
$917M
| $803 | ﹤0.01% |
6
-4
| -40% | -$535 |
|
2218
RxSight
RXST
$385M
| $791 | ﹤0.01% |
+23
| New | +$791 |
|
2219
Evolv Technologies
EVLV
$1.37B
| $790 | ﹤0.01% |
+200
| New | +$790 |
|
2220
Enhabit
EHAB
$411M
| $789 | ﹤0.01% |
101
-22
| -18% | -$172 |
|
2221
Treace Medical Concepts
TMCI
$470M
| $789 | ﹤0.01% |
+106
| New | +$789 |
|
2222
Movado Group
MOV
$441M
| $788 | ﹤0.01% |
+40
| New | +$788 |
|
2223
National Research Corp
NRC
$374M
| $777 | ﹤0.01% |
44
-112
| -72% | -$1.98K |
|
2224
Banc of California
BANC
$2.65B
| $773 | ﹤0.01% |
+50
| New | +$773 |
|
2225
First Bancorp
FNLC
$306M
| $766 | ﹤0.01% |
+28
| New | +$766 |
|